Page 1

BB Biotech Media release of October 22 , 2021 Interim report of BB Biotech AG as at September 30 , 2021 BB Biotech : Gains realized following COVID - 19 vaccine booster update enable increases in oncology and CNS Healthcare markets traded higher in July and August but lost ground in September and ended the third quarter in line with the broader market . BB Biotech shares showed a return of -3.3 % in CHF and -2.0 % in EUR for the third quarter of 2021. For the first nine months , their total return including the dividend stood at 18.2 % in CHF and 19.0 % in EUR . BB Biotech , an early investor in Moderna , took advantage of the company's fundamental strength to realize some profits , but remains substantially invested in the stock . The Investment Team did close its position in Halozyme after 11 years and realized a total profit of USD 235 mn on this investment . Most of the proceeds were reinvested in companies with an attractive oncology pipeline such as Revolution Medicines , Relay Therapeutics , Fate Therapeutics , Essa Pharma , Macrogenics , Molecular Templates and Mersana Therapeutics . IPO activities in the biotech sector have subsided somewhat , while takeovers remain at a low level . There is however a full pipeline of pending regulatory approvals and clinical trial readouts . The MSCI World Healthcare Index ( + 1.1 % in USD ) and Nasdaq Biotech Index ( -1.1 % in USD ) consolidated over the first nine months of the year . Yet within these indices there was a substantial performance dispersion , particularly in the NBI index . Smaller and mid cap biotechnology companies continued to underperform in the third quarter , as reflected , for example , by the XBI , an S & P biotechnology ETF , at -7.2 % ( in USD ) . The limited appetite for earlier stage , smaller and mid cap biotechnology companies reduced and cooled the previously robust IPO action . BB Biotech's third quarter and first nine months 2021 performance BB Biotech's third quarter 2021 share price performance was -3.3 % in CHF and -2.0 % in EUR . The Net Asset Value ( NAV ) pulled back 5.2 % in CHF , 3.5 % in EUR and 6.1 % in USD . Consequently , the net loss was CHF 208 mn compared to a net loss of CHF 395 mn for the same period in 2020. Despite the third quarter pullback , BB Biotech's total share price return for the first nine months of 2021 was 18.2 % in CHF and 19.0 % in EUR , including the dividend . This was well ahead of the Net Asset Value appreciation of 3.2 % in CHF , 3.5 % in EUR and -2.0 % in USD . The resulting net profit of CHF 141 mn for the first nine months of 2021 compares to a profit of CHF 26 mn for the same period of 2020. Exchange - rate fluctuations in the USD / CHF currency pair contributed approximately 5.3 % to first nine months 2021 performance . Selective portfolio adjustments The Investment Team continued to reshape the portfolio . Moderna's inclusion in the S & P500 and evolving SARS- CoV - 2 patterns in August 2021 propelled its share price to all - time highs , making it the most valuable biotechnology company . Moderna's promising outlook and the ascendancy of mRNA technology has allowed BB Biotech to realize further profits from this long - term investment . Another long - term investment cycle with Halozyme allowed the Investment Team to exit the position with substantial ( USD 235 mn ) profits over the eleven - year investment cycle . The capital released from Moderna and Halozyme was reinvested in three subsectors . Most was allocated to oncology pipeline companies such as Revolution Medicines , Relay Therapeutics , Fate Therapeutics , Essa Pharma , Macrogenics , Molecular Templates and Mersana Therapeutics . The Investment Team also took on more exposure to the CNS space , increasing the Sage Therapeutics and Intra - Cellular Therapies positions . Existing positions in Myovant and Radius , smaller commercial - stage companies , were also expanded . With 32 positions in the portfolio , during the third quarter 2021 the investment level decreased slightly from 107.5 % to 106.8 % . This infers capital flexibility to continue investing in new opportunities within the established guidelines . Third - quarter 2021 developments in the portfolio Moderna presented impressive COVID - 19 boost injection data . Management also outlined its strategy to leverage its mRNA platform with new prophylactic vaccines . The company demonstrated that the third “ booster shot " , at half BB Biotech AG www.bbbiotech.com Schwertstrasse 6 T +41 52 624 08 45 CH - 8200 Schaffhausen